5
Clinical data
A placebo-controlled phase 1 clinical trail of 37 subjects studied the effects of oral racemic LA in
multiple sclerosis. Subjects were randomly assigned to 4
groups, including placebo. The other 3 groups received LA 600 mg twice a day, 1,200 mg once a day, or 1,200 mg twice a day, for 14 days. The study found LA to be generally well tolerated, but peak plasma levels of LA varied among subjects.